Decreased BDNF levels in amygdala and hippocampus after intracerebroventricular administration of ouabain

Authors

  • Luciano K. Jornada University of Southern Santa Catarina; Postgraduate Program in Health Sciences; Health Sciences Unit
  • Samira S. Valvassori Federal University of Rio Grande do Sul; Institute for Translational Medicine; Laboratory of Molecular Psychiatry and National Science and Technology; Bipolar Disorders Program
  • Wilson R. Resende University of Southern Santa Catarina; Postgraduate Program in Health Sciences; Health Sciences Unit
  • Morgana Moretti University of Southern Santa Catarina; Postgraduate Program in Health Sciences; Health Sciences Unit
  • Camila L. Ferreira University of Southern Santa Catarina; Postgraduate Program in Health Sciences; Health Sciences Unit
  • Gabriel R. Fries Federal University of Rio Grande do Sul; Institute for Translational Medicine; Laboratory of Molecular Psychiatry and National Science and Technology; Bipolar Disorders Program
  • Flavio Kapczinski Federal University of Rio Grande do Sul; Institute for Translational Medicine; Laboratory of Molecular Psychiatry and National Science and Technology; Bipolar Disorders Program
  • João Quevedo São José Hospital; Research Center; Laboratory of Translational Psychiatry

DOI:

https://doi.org/10.1590/S0101-60832012000500002

Keywords:

BDNF, mania, Na/K ATPase, ouabain

Abstract

OBJECTIVE: The present study aims to investigate the effects of ouabain intracerebroventricular injection on BDNF levels in the amygdala and hippocampus of Wistar rats. METHODS: Animals received a single intracerebroventricular injection of ouabain (10-3 and 10-2 M) or artificial cerebrospinal fluid and immediately, 1h, 24h, or seven days after injection, BDNF levels were measured in the rat's amygdala and hippocampus by sandwich-ELISA (n = 8 animals per group). RESULTS: When evaluated immediately, 3h, or 24h after injection, ouabain in doses of 10-2 and 10-3 M does not alter BDNF levels in the amygdala and hippocampus. However, when evaluated seven days after injection, ouabain in 10-2 and 10-3 M, showed a significant reduction in BDNF levels in both brain regions evaluated. DISCUSSION: In conclusion, we propose that the ouabain decreased BDNF levels in the hippocampus and amygdala when assessed seven days after administration, supporting the Na/K ATPase hypothesis for bipolar illness.

Downloads

Download data is not yet available.

Downloads

Published

2012-01-01

Issue

Vol. 39 No. 5 (2012)

Section

Original Articles

License

Once accepted for publication, the manuscript becomes permanent property of the Archives of Clinical Psychiatry. This copyright transfer subsumes exclusive and unlimited entitlement of the Archives of Clinical Psychiatry to publish and distribute the full contents of articles in whichever publishing medium, including press and electronic media, in Brazil and abroad.

Manuscripts are accepted with the understanding that the Editor and the editorial staff have the right to make revisions aimed at greater conciseness, clarity, and conformity with Journal style, of course without changing its content.

How to Cite

Decreased BDNF levels in amygdala and hippocampus after intracerebroventricular administration of ouabain. (2012). Archives of Clinical Psychiatry, 39(5), 157-160. https://doi.org/10.1590/S0101-60832012000500002